Tvardi Therapeutics
TVRD
97 hedge funds and large institutions have $21.7M invested in Tvardi Therapeutics in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 33 reducing their positions, and 23 closing their positions.
1,050% more call options, than puts
Call options by funds: $46K | Put options by funds: $4K
20% more capital invested
Capital invested by funds: $18.1M → $21.7M (+$3.57M)
1.58% less ownership
Funds ownership: 44.78% → 43.2% (-1.6%)
11% less funds holding
Funds holding: 109 → 97 (-12)
27% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 33
52% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$1.12M |
| 2 |
Renaissance Technologies
New York
|
+$458K |
| 3 |
AI
Acuitas Investments
Seattle,
Washington
|
+$369K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$309K |
| 5 |
Millennium Management
New York
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$590K |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$576K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$518K |
| 4 |
Morgan Stanley
New York
|
-$135K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$130K |
TVRD Hedge Fund Activity: Q1 2024 in Review
97 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2024, worth a combined $21.7M — up 20% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of TVRD and 11 opened new positions — a net loss of 12 holders — while 33 trimmed existing stakes and 24 added.
The largest buyer was Rosalind Advisors, opening a new position worth an estimated $1.12M. The largest seller was Federated Hermes, cutting an estimated $590K.
- 97 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2024, down from 109 in Q4 2023.
- Funds reported $21.7M of Tvardi Therapeutics stock for Q1 2024, up 20% quarter-over-quarter.
- 11 funds opened new Tvardi Therapeutics positions in Q1 2024 and 23 closed out, a net change of -12 holders.
- The largest Tvardi Therapeutics buyer in Q1 2024 was Rosalind Advisors, an estimated $1.12M added.
- The largest Tvardi Therapeutics seller in Q1 2024 was Federated Hermes, an estimated $590K sold.
Based on aggregated 13F filings for Q1 2024.